Cyclacel Pharmaceuticals, Inc. (CYCCP)
-NasdaqCM 7.00 
0.20(2.78%) May 16 - Nasdaq Real Time Price
| Prev Close: | 7.00 |
|---|
| Open: | N/A |
|---|
| Bid: | 7.65 x 600 |
|---|
| Ask: | 8.26 x 800 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.06 - 10.45 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 341 |
|---|
| Market Cap: | 76.17M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cyclacel Pharmaceuticals Announces $20 Million Underwritten OfferingGlobeNewswire(Thu, May 16)
- Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire(Wed, May 15)
- Cyclacel Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 10)
- Cyclacel Pharmaceuticals' Convertible Exchangeable Preferred Stock Shares Cross 8% Yield Markat Forbes(Mon, May 6)
- Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDSGlobeNewswire(Tue, Apr 30)
- Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare ConferenceGlobeNewswire(Tue, Apr 23)
- Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACRGlobeNewswire(Tue, Apr 9)
- AACR Press Conference Highlights Combination Potential of Two Cyclacel DrugsGlobeNewswire(Mon, Apr 8)
- Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent LitigationGlobeNewswire(Thu, Apr 4)
- Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual MeetingGlobeNewswire(Wed, Apr 3)
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial ResultsGlobeNewswire(Wed, Mar 27)
- Cyclacel to Announce Year-End and Fourth Quarter 2012 Financial ResultsGlobeNewswire(Fri, Mar 22)
- Cyclacel Pharmaceuticals' Convertible Exchangeable Preferred Shares Cross 7% Yield Markat Forbes(Fri, Jan 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 271.06 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases.
View More